Prognostic value of lymph node ratio and extramural vascular invasion on survival for patients undergoing curative colon cancer resection

被引:0
作者
C N Parnaby
N W Scott
G Ramsay
C MacKay
L Samuel
G I Murray
M A Loudon
机构
[1] Aberdeen Royal Infirmary,Department of Surgery
[2] Medical Statistics Team,Department of Oncology
[3] University of Aberdeen,Department of Pathology
[4] Aberdeen Royal Infirmary,undefined
[5] Aberdeen Royal Infirmary,undefined
来源
British Journal of Cancer | 2015年 / 113卷
关键词
lymph node ratio; extramural vascular invasion; colon cancer; prognosis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:212 / 219
页数:7
相关论文
共 161 条
[1]  
Baxter NN(2010)An evaluation of the relationship between lymph node number and staging in pT3 colon cancer using population-based data Dis Colon Rectum 53 65-70
[2]  
Ricciardi R(2005)Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes J Clin Oncol 23 8706-8712
[3]  
Simunovic M(2012)Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting Cancer 118 628-638
[4]  
Urbach DR(2013)Prognostic significance of extramural vascular invasion in T4 rectal cancer Colorectal Dis 15 e665-e671
[5]  
Virnig BA(2006)Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study J Surg Oncol 93 439-445
[6]  
Berger AC(2006)More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study Ann Surg 244 602-610
[7]  
Sigurdson ER(2010)The optimal number of lymph nodes examined in stage II colorectal cancer and its impact of on outcomes BMC Cancer 10 267-389
[8]  
LeVoyer T(2002)Lymph node recovery from colorectal tumor specimens: recommendation for a minimum number of lymph nodes to be examined World J Surg 26 384-156
[9]  
Hanlon A(2009)Extramural vascular invasion is an adverse prognostic indicator of survival in patients with colorectal cancer Colorectal Dis 11 150-1233
[10]  
Mayer RJ(2012)Bevacizumab plus oxaliplatin as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial Lancet Oncol 13 1225-365